Literature DB >> 22318024

Fresh from the biotech pipeline--2011 [corrected].

Jim Kling.   

Abstract

Mesh：

Year:  2012        PMID： 22318024     DOI： 10.1038/nbt.2111

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Incyte comes of age with JAK inhibitor approval.

Authors:  Nuala Moran
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

3.  Seattle Genetics rare cancer drug sails through accelerated approval.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

4.  The discovery and development of belimumab: the anti-BLyS-lupus connection.

Authors:  William Stohl; David M Hilbert
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908
  4 in total
  1 in total

Review 1.  Biologics: the role of delivery systems in improved therapy.

Authors:  Nataša Skalko-Basnet
Journal:  Biologics       Date:  2014-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.